Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). The result of our efforts are SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapies that can recognize cancer proteins, and as a result detect and fight cancer within patients.
SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP, and NY-ESO are moving through clinical studies in multiple cancer types.
|$5.43 0.07 (1.27%)Data provided by Nasdaq. Minimum 15 minutes delayed.|
|11/06/18||Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update|
|Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells
Continued dosing in Cohort 1 of AFP study, with anticipated dose escalation to Cohort 2 early 2019
~$26 million upon completion of transition of NY-ESO SPEAR T-cell program IND to GSK
Closed registered direct offering with net proceeds of ~$100 million; guidance updated,
funded to late 2020
Conference call to be held toda... |
|10/25/18||Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018|
|PHILADELPHIA and OXFORD, United Kingdom, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Third Quarter 2018 and provide a general business update before the U.S. markets open on Tuesday, November 6, 2018. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) on the same day.
The press release and the live webcast of ... |
|10/20/18||Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress|
|PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the first two cohorts of its ongoing studies with its MAGE-A10 and MAGE-A4 SPEAR T-cells in two poster presentations earlier today at the European Society for Medical Oncology (ESMO) Congress in Munich, Germany.
“We are encouraged by the safety data from these initial cohorts, which inc... |
|10/08/18||Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress|
|PHILADELPHIA and OXFORD, United Kingdom, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced further details about two poster presentations at the upcoming ESMO congress, as follows:
MAGE-A10 poster for discussion presentation details:
A late-breaking abstract with data from the two ongoing MAGE-A10 studies (“triple tumor” and lung) was accepted for poster discussion, with the full ab... |
|There are currently no events scheduled.|
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.|